The present invention provides a dry powder inhaler comprising: a reservoir containing a dry powder formulation and an arrangement for delivering a metered dose of the medicament from the reservoir; a cyclone deagglomerator for breaking up agglomerates of the dry powder medicament; and a delivery passageway for directing an inhalation-induced air flow through a mouthpiece, the delivery passageway extending to the metered dose of medicament, wherein the formulation comprises an inhalable β.sub.2-agonist having a particle size distribution of d1O<1 μπ.Math.=1-3 μπ.Math., d90=3.5-6 μm and NLT 99% 10 μm and a lactose carrier.

The present invention provides a dry powder inhaler comprising: a reservoir containing a dry powder formulation and an arrangement for delivering a metered dose of the medicament from the reservoir; a cyclone deagglomerator for breaking up agglomerates of the dry powder medicament; and a delivery passageway for directing an inhalation-induced air flow through a mouthpiece, the delivery passageway extending to the metered dose of medicament, wherein the formulation comprises an inhalable β.sub.2-agonist having a particle size distribution of d1O<1 μπ.Math.=1-3 μπ.Math., d90=3.5-6 μm and NLT 99% 10 μm and a lactose carrier.

A GRK2 protein inhibitor compound of Formula I

##STR00001##

wherein X is an atom selected from carbon and nitrogen, and
R.sub.1 is selected from the groups methyl carboxylate and 1,3,4-oxadiazol-2-yl and wherein the compound is selected from methyl 4-(naphthalene-2-amido)benzoate and N-[4-(1,3,4-oxadiazol-2-yl)phenyl]quinoline-3-carboxamide. Also disclosed are pharmaceutical compositions comprising at least a compound of Formula I.

A GRK2 protein inhibitor compound of Formula I

##STR00001##

wherein X is an atom selected from carbon and nitrogen, and
R.sub.1 is selected from the groups methyl carboxylate and 1,3,4-oxadiazol-2-yl and wherein the compound is selected from methyl 4-(naphthalene-2-amido)benzoate and N-[4-(1,3,4-oxadiazol-2-yl)phenyl]quinoline-3-carboxamide. Also disclosed are pharmaceutical compositions comprising at least a compound of Formula I.

The present invention relates to a pharmaceutical composition comprising trimebutine as an active ingredient for prevention or treatment of cancer. Having an excellent effect of selectively inhibiting growth and proliferation of cancer stem cells, the pharmaceutical composition can suppress the recurrence, metastasis, and progression of cancer even when used alone. Thus, the composition can be advantageously used as a pharmaceutical composition for prevention or treatment of cancer or in combination with other agents.

The present invention relates to a pharmaceutical composition comprising trimebutine as an active ingredient for prevention or treatment of cancer. Having an excellent effect of selectively inhibiting growth and proliferation of cancer stem cells, the pharmaceutical composition can suppress the recurrence, metastasis, and progression of cancer even when used alone. Thus, the composition can be advantageously used as a pharmaceutical composition for prevention or treatment of cancer or in combination with other agents.

The present invention relates to a pharmaceutical composition comprising trimebutine as an active ingredient for prevention or treatment of cancer. Having an excellent effect of selectively inhibiting growth and proliferation of cancer stem cells, the pharmaceutical composition can suppress the recurrence, metastasis, and progression of cancer even when used alone. Thus, the composition can be advantageously used as a pharmaceutical composition for prevention or treatment of cancer or in combination with other agents.

The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. Said composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.

The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. Said composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.

A particulate, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described.